

# Xiaofeng Yuan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4736901/publications.pdf>

Version: 2024-02-01

8  
papers

66  
citations

1937685  
4  
h-index

1588992  
8  
g-index

9  
all docs

9  
docs citations

9  
times ranked

84  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tspan9 Induces EMT and Promotes Osteosarcoma Metastasis via Activating FAK-Ras-ERK1/2 Pathway. <i>Frontiers in Oncology</i> , 2022, 12, 774988.	2.8	8
2	Nanocomposite coating of albumin/Li-containing bioactive glass nanospheres promotes osteogenic activity of PEEK. <i>Journal of Materials Science: Materials in Medicine</i> , 2021, 32, 120.	3.6	3
3	Erythrocyte membrane protein band 4.1-like 3 inhibits osteosarcoma cell invasion through regulation of Snai1-induced epithelial-to-mesenchymal transition. <i>Aging</i> , 2021, 13, 1947-1961.	3.1	8
4	Loss of histone H4 lysine 20 trimethylation in osteosarcoma is associated with aberrant expression of histone methyltransferase SUV420H2. <i>Oncology Letters</i> , 2020, 20, 26.	1.8	4
5	Knockdown of NSD2 Suppresses Renal Cell Carcinoma Metastasis by Inhibiting Epithelial-Mesenchymal Transition. <i>International Journal of Medical Sciences</i> , 2019, 16, 1404-1411.	2.5	12
6	Pivotal roles of protein 4.1B/DAL-1, a FERM domain containing protein, in tumor progression (Review). <i>International Journal of Oncology</i> , 2019, 55, 979-987.	3.3	1
7	Histone methyltransferase SUV39H2 serves oncogenic roles in osteosarcoma. <i>Oncology Reports</i> , 2018, 41, 325-332.	2.6	7
8	The role of histone lysine methyltransferase NSD3 in cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3847-3852.	2.0	22